Several clinical trials are currently testing CSF-1/CSF-1R targeting agents (including the Novartis small-molecule inhibitor BLZ945 and Roche monoclonal antibody RG7155) in, among others, breast cancer, glioma, melanoma, ovarian cancer, and lung cancer (Table 1) (132). This evidence concerns the gene CSF1R and melanoma.